The subject of this publication is the conclusion of a contract in accordance with Section 130a (8) SGB V for the following active substance as part of a so-called open house procedure:

Pegfilgrastim (L03AA13)

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredient under standardized contract conditions and a standardized access procedure.

The earliest contract start is 1.5.2021. Based on this, the contract term is a maximum of 24 months.

Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the named active ingredient.

The earliest contract start is 1.5.2021. Based on this, the contract term is a maximum of 24 months.